Qiagen NVXTER:QIA +0.74%71 EBITDA Margin % is 30.08% as of Mar. 2026, which is 11% below its 10-year median of 33.79. GuruFocus rates XTER:QIA with a GF Score™ of 71/100 and a GF Value™ of €45.90 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Qiagen NV ranks better than 94.09% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Qiagen NV's EBITDA for the
three
months ended in Mar. 2026 was €128 Mil. Qiagen NV's Revenue for the
three
months ended in Mar. 2026 was €426 Mil. Therefore, Qiagen NV's EBITDA margin for the quarter that ended in Mar. 2026 was 30.08%.
Qiagen NV (XTER:QIA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Qiagen NV EBITDA Margin % Related Terms
Qiagen NV EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Qiagen NV's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:QIA vs TWST, CRL, BLLN: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Qiagen NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qiagen NV EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Qiagen NV's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (XTER:QIA) has a EBITDA Margin % of 30.08% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qiagen NV and its competitors. This is 11% below median its historical median of 33.79. Over the past decade, Qiagen NV's EBITDA Margin % has ranged from 14.93 to 39.76. According to the industry distribution chart, Qiagen NV ranks #12 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 5.9%.
Is Qiagen NV's EBITDA Margin % too high?
Qiagen NV's current EBITDA Margin % of 30.08% is 11% below median its 10-year median of 33.79. Over the past 10 years, this metric has ranged from a low of 14.93 to a high of 39.76. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Qiagen NV's value of 30.08% is 501.6% above this industry median. Based on the distribution chart, Qiagen NV ranks #12 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Qiagen NV has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's EBITDA Margin % compare to TWST and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #12 out of 203 companies for EBITDA Margin %. This places Qiagen NV in the top 6% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Qiagen NV's value of 30.08% is 501.6% above this benchmark. Historically, Qiagen NV's own EBITDA Margin % has ranged from 14.93 to 39.76 over the past decade. While the company's 10-year median is 33.79 vs. the industry median of 5.00, Qiagen NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qiagen NV's current EBITDA Margin % of 30.08% is 501.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qiagen NV and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qiagen NV's current EBITDA Margin % is 30.08%, which is 11% below median its own 10-year median of 33.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.90, compared to a current price of €34.57 — trading 24.7% below its estimated fair value. The current EBITDA Margin % is 30.08%, which is 11% below median its 10-year median of 33.79 and 501.6% above the Medical Diagnostics & Research industry median of 5.00. Qiagen NV's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current EBITDA Margin % is 30.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (XTER:QIA) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of €34.57 is trading 24.7% below its estimated GF Value™ of €45.90.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for XTER:QIA:
EBITDA Margin %: 30.08% (11% below median its 10-year median of 33.79)
GF Value™: €45.90 vs. price of €34.57 (24.7% below fair value)
Industry Position: 501.6% above the Medical Diagnostics & Research median (#12 of 203)
No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
71GF Score
Get the complete analysis for XTER:QIA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:QIA has been successfully added to your 
